|
Lymphomas
Common Treatments
Commonly Used Medications for Hodgkin Lymphoma
|
Chemotherapy |
bleomycin (Blenoxane) |
brentuximab vedotin (Adcetris) |
chlorambucil (Leukeran) |
cyclophosphamide |
dacarbazine (DTIC-Dome) |
doxorubicin hydrochloride (Adriamycin) |
mechlorethamine (Mustargen) |
nivolumab (Opdivo) |
pembrolizumab (Keytruda) |
prednisone |
procarbazine (Matulane) |
vinblastine (Velban) |
vincristine (Oncovin) |
Some Possible Combination Therapies |
AAVD: doxorubicin (Adriamycin), brentuximab vedotin (Adcetris), vinblastine (Velban) and dacarbazine (DTIC-Dome) |
ABVD: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban) and dacarbazine (DTIC-Dome) |
ABVD + R: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), dacarbazine (DTIC-Dome) and rituximab (Rituxan) |
BEACOPP: bleomycin (Blenoxane), etoposide (Etopophos), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine (Matulane) and prednisone |
ChlVPP: chlorambucil (Leukeran), vinblastine (Velban), procarbazine (Matulane) and prednisone |
DHAP: dexamethasone, high-dose cytarabine and cisplatin |
ESHAP: etoposide (Etopophos), methylprednisolone, high-dose cytarabine and cisplatin |
GDP: gemcitabine (Gemzar), dexamethasone and cisplatin |
Gem-Ox: gemcitabine (Gemzar) and oxaliplatin (Eloxatin) |
GVD: gemcitabine (Gemzar), vinorelbine (Navelbine) and doxorubicin |
ICE: ifosfamide, carboplatin and etoposide (Etopophos) |
Stanford V: doxorubicin (Adriamycin), mechlorethamine (Mustargen), vincristine (Oncovin), bleomycin (Blenoxane), etoposide (Etopophos) and prednisone |
As of 12/18/20
Commonly Used Medications for Non-Hodgkin Lymphoma
|
Chemotherapy |
acalabrutinib (Calquence) |
axicabtagene ciloleucel (Yescarta) |
bendamustine (Bendeka) |
bleomycin (Blenoxane) |
bortezomib (Velcade) |
brentuximab vedotin (Adcetris) |
brexucabtagene autoleucel (Tecartus) |
carboplatin |
chlorambucil (Leukeran) |
cisplatin |
copanlisib (Aliqopa) |
cyclophosphamide |
dexamethasone |
doxorubicin hydrochloride (Adriamycin) |
duvelisib (Copiktra) |
ibritumomab (Zevalin) |
ibrutinib (Imbruvica) |
idelalisib (Zydelig) |
lenalidomide (Revlimid) |
mechlorethamine (Mustargen) |
methotrexate |
methylprednisolone |
mogamulizumab-kpkc (Poteligeo) |
obinutuzumab (Gazyva) |
pembrolizumab (Keytruda) |
prednisone |
procarbazine (Matulane) |
rituximab (Rituxan) |
rituximab and hyaluronidase human (Rituxan Hycela) |
rituximab-abbs (Truxima) |
rituximab-arrx (Riabni) |
rituximab-pvvr (Ruxience) |
selinexor (Xpovio) |
tazemetostat (Tazverik) |
tisagenlecleucel (Kymriah) |
venetoclax (Venclexta) |
vinblastine (Velban) |
vincristine (Oncovin) |
zanubrutinib (Brukinsa) |
Some Possible Combinations |
BR: bendamustine (Bendeka) and rituximab (Rituxan) |
CHOP: cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone |
CODOX-M/IVAC: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and intrathecal methotrexate, and cytarabine followed by high-dose systemic methotrexate and rituximab (Rituxan) |
CVP: cyclophosphamide, vincristine (Oncovin) and prednisone |
EPOCH-R: etoposide (Etopophos), prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin (Adriamycin) and rituximab (Rituxan) |
Hyper-CVAD: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and dexamethasone, alternating with high-dose methotrexate plus cytarabine and rituximab (Rituxan) |
lenalidomide (Revlimid) with rituximab product |
P+BR: polatuzumab (Polivy), bendamustine (Bendeka) and rituximab (Rituxan) |
polatuzumab vedotin-piiq (Polivy) with bendamustine (Bendeka) and a rituximab product |
R-CHOP: rituximab (Rituxan), cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone |
R-CVP: rituximab (Rituxan), cyclophosphamide, vincristine (Oncovin) and prednisone |
rituximab and hyaluronidase human (Rituxan Hycela) with first-line chemotherapy |
tafasitamab-cxix (Monjuvi) with lenalidomide (Revlimid) |
As of 12/18/20
|